冠科美博（Apollomics）Uproleselan 注射液（APL-106）用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 – (亚太商讯 via SEAPRWire.com) – 冠科美博（Apollomics Inc...
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, China, Gaithersburg, MD, Jan 7, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- […]